Home › Multiple Myeloma › Colorado › Denver
Pag-aaral pangklinika para sa Multiple Myeloma sa Denver, CO
26 pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Denver (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Colorado Blood Cancer Institute, Denver
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Nagre-recruitPhase 1
- Colorado Blood Cancer Institute, Denver
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Colorado Blood Cancer Institute, Denver
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Nagre-recruitPhase 3
- Research Site, Denver
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Nagre-recruitPhase 1
- Colorado Blood Cancer Institute /ID# 280275, Denver
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Nagre-recruitPhase 1/2
- Colorado Blood Cancer Institute /ID# 273129, Denver
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Nagre-recruitPhase 2/3
- Colorado Blood Cancer Institute /ID# 279080, Denver
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1/2
- Research Site, Denver
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Nagre-recruitPhase 3
- CBCI, Colorado Blood Cancer Institute, Denver
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Nagre-recruitPhase 1/2
- Research Site, Denver
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Colorado Blood Cancer Institute, Denver
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Nagre-recruitPhase 3
- Research Site, Denver
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Colorado Blood Cancer Institute, Denver
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
Nagre-recruitPhase 1
- Colorado Blood Cancer Institute, Denver
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Nagre-recruitPhase 1
- Research Site, Denver
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Nagre-recruitPhase 2
- Colorado Blood Cancer Institute, Denver
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Nagre-recruitPhase 1/2
- Colorado Blood Cancer Institute/SCRI, Denver
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Nagre-recruitPhase 3
- Research Site, Denver
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)
Nagre-recruitPhase 2
- Colorado Blood Cancer Institute, Denver
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Nagre-recruitPhase 2
- Colorado Blood Cancer Institute, Denver
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Colorado Blood Cancer Institute /ID# 273751, Denver
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Nagre-recruitPhase 2
- Colorado Blood Cancer Institute, Denver
- Rocky Mountain Cancer Center, Denver
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Nagre-recruitPhase 1/2
- Colorado Blood Cancer Institute, Denver
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Colorado Blood Cancer Institute, Denver
Pag-aaral para sa Multiple Myeloma sa ibang lungsod
- New York City, NY59 pag-aaral
- Boston, MA45 pag-aaral
- Atlanta, GA42 pag-aaral
- Houston, TX39 pag-aaral
- Durham, NC36 pag-aaral
- Nashville, TN31 pag-aaral
- St. Louis, MO26 pag-aaral
- Rochester, MN25 pag-aaral
- Columbus, OH25 pag-aaral
- Chicago, IL24 pag-aaral
- Milwaukee, WI23 pag-aaral
- Baldwin Park, CA23 pag-aaral
Iba pang pag-aaral sa Denver
- Kanser sa Suso26 pag-aaral
- Non-Small Cell Lung Cancer25 pag-aaral
- Metastatic Cancer25 pag-aaral
- Colorectal Cancer22 pag-aaral
- Melanoma19 pag-aaral
- Kanser sa Prostate19 pag-aaral
- Kanser sa Ovary17 pag-aaral
- Kanser ng Endometrium15 pag-aaral
- Kanser (lahat ng uri)15 pag-aaral
- Kanser sa Baga15 pag-aaral
- Non-Hodgkin Lymphoma14 pag-aaral
- Kanser sa Pancreas13 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.